TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 3 | 1 | 3 | -0 | -4 | 7 | 17 | 27 | 35 | 14 |
| P | %wins | 67 | 0 | 67 | 100 | 100 | 67 | 67 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
9/15/14 14:41 | 9/15/14 | OREX | Orexigen Therapeutics, Inc. | DE | Health | Drug | Pharmaceutical Preparations | Narachi Michael | CA | DO | P,CEO | P | 239 | 4.78 | 3 | 50 | 623 | 58 | D | -1 | -23 | -26 | -12 | 4 | -10 | -11 | -12 | -5 | -8 | -37 | 12 | 35 | -51 |
2/6/14 15:50 | 2/4/14 | CLDN | Celladon Corp | DE | Health | BioPrd | Biological Products, (No Diag | Narachi Michael | CA | D | P | 500 | 8.00 | 4 | 63 | New | 63 | D | -9 | 2 | -2 | 49 | 31 | 37 | 109 | ||||||||
5/29/12 14:17 | 5/24/12 | AMAG | Amag Pharmaceuticals Inc. | DE | Health | Drug | Pharmaceutical Preparations | Narachi Michael | MA | D | P.m | 27 | 3.61 | 3 | 8 | New | 8 | D | -57 | -14 | -16 | -16 | -11 | -14 | 11 | 5 | 2 | -1 | 9 | 8 | 8 | 48 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |